Research Site
Petoskey, Michigan 49770
1 studies enrolling now · 15 studies all time
What they study most
Acute Coronary Syndrome, Anemia, Atherothrombosis, Carcinoma, Cardiovascular Death, Cardiovascular Disease, Chronic Heart Failure, Congestive Heart Failure, Coronary Arteriosclerosis, Coronary Atherosclerosis, Cost Sharing, Acute Coronary Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Studies at this site
- Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure — Completed
- DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction — Completed
- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
- Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
- Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound — Completed
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
- JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events — Stopped early
- A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA) — Completed
- Iressa Expanded Access Program (EAP) — Completed
- CRESTOR Athero Imaging Head to Head IVUS Study — Completed
- A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) — Completed
- GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus — Stopped early